350 rub
Journal №3 for 2012 г.
Article in number:
Vascular endothelial growth factor in diabetic retinopathy and diabetic macular edema development in patients with diabetes mellitus type 2
Keywords: diabetes mellitus type 2 diabetic retinopathy growth factors vascular endothelial growth factor diabetic macular edema
Authors:
I.V. Vorobieva, D.A. Merkushenkova, L.G. Estrin
Abstract:
Diabetic retinopathy (DR) is a common vascular complication of diabetes and is one of the first place among the causes complete loss of vision. The danger of this complication is that the diabetic retinal vascular damage for a long time unnoticed. In the early stages of diabetic retinopathy patients were not mark reduced vision, and only when the changes apply to the central area of the retina or extensive hemorrhage happen, visit a doctor. Triggered the development of diabetic retinopathy is hyperglycemia. Hyperglycemia plays a critical role in increasing retinal perfusion, which is a key pathogenetic factor in the genesis and progression of DR. Retinal blood flow depends on the level of glucose, therefore, not only chronic, but an urgent hyperglycemia are dangerous. Along with these recent years, characterized by increasing interest of researchers to oxidative stress as one of the key mechanisms of diabetic angiopathy. In the development of oxidative stress in type 2 diabetes and the pathogenesis of diabetic angiopathies leading role is played polymorphonuclear neutrophils. It is established that elastase neutrophils has a high proteolytic activity. The appearance of elastase in tissue, blood, tears - the main link in the pathogenesis of many diseases. As a biochemical marker of inflammation, elastase may play a crucial role in the pathogenesis of thrombohemorrhagic complications. As indicated above to determine the level of activity of leukocyte elastase is an important indicator not only of the intensity level of the inflammatory response, but also at high risk for thrombohemorrhagic violations. Natural regulator of the activation of elastase is α - 1 - proteinase inhibitor (α -1 - PI), one of the major acute phase proteins of inflammation. The natural regulator the activation of elastase is α - 1 - proteinaseinhibitor (α -1 - PI), one of the major acute phase proteins of inflammation. Seems promising study the activity of elastase and α -1 - PI as indicators of oxidative stress and high risk for complications of DR. It is possible to extend an adequate assessment of the disease and monitoring treatment effectiveness.
Pages: 48-54
References
  1. Астахов Ю.С., Григорьева Н.Н., Шкляров Е.Б., Щадричев Ф.Е. Сравнение различных методов скрининга диабетической ретинопатии // Материалы Научно-практической конференции «Сахарный диабет и глаз». 2006. С. 24.
  2. Балаболкин М.И., Клебанова Е.М., Креминская В.М. Патогенез ангиопатий при сахарном диабете // Сахарный диабет. 1999. № 1. С. 2-8.
  3. Балашевич Л.И. Глазные проявления диабета. СПб: Издательский дом СПбМАПО. 2004. С. 365.
  4. Будзинская М.В. Система новых подходов к диагностике и лечению субретинальной неоваскулярной мембраны: Автореф. - дисс. д-ра мед. наук. Москва. 2011. С. 44.
  5. Воробьева И.В., Репкина М.Ю. Основные механизмы патогенеза диабетической ретинопатии (обзор литературы) // «VII Всероссийская школа офтальмологов»: Сб. науч. тр. М.: 2008. С. 232-240.
  6. Воробьева И.В., Эстрин Л.Г., Репкина М.Ю. Диабетический макулярный отек // Сб. «Успехи теоретической и клинической медицины». Москва. 2008. Вып. 7. Т. 1. С. 220-222.
  7. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное руководство. М.: Гэотар-Медия. 2009. С. 254.
  8. Дедов И.И., Шестакова М.В. Сахарный диабет и артериальная гипертензия // М.: ООО «Медицинское информационное агентство». 2006. C. 344.
  9. Ермакова Н. А., Сыроедова О. Н., Анциферов М. Б., Балацкая Н. В., Краснова Л. Б. Роль фактора роста эндотелия сосудов в развитии диабетической ретинопатии у больных сахарным диабетом 1-го типа // Вестник офтальмологии. 2008. № 1. 25-28.
  10. Ермакова Н.А., Анциферов М.Б., Климова Н.В. Распространенность диабетической ретинопатии у больных сахарным диабетом 1 и 2 типа // Новые технологии в офтальмологии: сб. науч. трудов. Чебоксары. 2007. С. 116-118.
  11. Измайлов А.С. Диабетическая ретинопатия и макулярный отек (диагностика и лазерное лечение): Автореф. ... дис. д-ра мед. наук. Санкт-Петербург. 2004. 399 с.
  12. Кацнельсон Л.А., Форофонова Т.И., Бунин А.Я. Сосудистые заболевания глаза // М.: Медицина. 1990. С. 272.
  13. Марри Р., Греннер Д., Мейес П., Родуэлл В. Биохимия человека. В 2-х т. М.: Мир. 1993. С. 803.
  14. Мошетова Л.К., Аржиматова Г.Ш., Строков И.А., Яровая Г.А. Современная антиоксидантная терапия диабетической ретинопатии // РМЖ. 2006. Т. 7. № 1. С. 36-38.
  15. Мошетова Л.К., Голубева И.В. Проведение скрининга диабетической ретинопатии в условиях городской поликлиники // Успехи теоретической и клинической медицины. 1999. № 3. С. 326 - 327.
  16. Мушкамбаров Н.Н., Кузнецов С.Л. Молекулярная биология: учебное пособие для студентов медицинских ВУЗов. М.: ООО «Медицинское информационное агенство». 2007. С. 536.
  17. Нероев В.В., Сарыгина О.И., Левкина О.А. Роль сосудистого эндотелиального фактора роста в патогенезе диабетической ретинопатии // Вестник офтальмологии. 2009. № 2. С. 58-60.
  18. Репкина М.Ю. Профилактика прогрессирования диабетической ретинопатии с контролем биомаркеров метаболических нарушений: Автореф. - дисс. канд. мед. наук. Москва. 2010. С.182.
  19. Стволовые клетки и регенеративная медицина / под ред. В.А. Ткачука. М.: Макс Пресс. 2011. С. 659.
  20. Сыроедова О.Н. Факторы риска развития диабетической ретинопатии: Автореф. ?  дисс. канд. мед. наук. Москва. 2009. С. 178.
  21. Трахтенберг Ю.А. Комплексная терапия диабетической ретинопатии у пациентов с сахарным диабетом 2 типа: Автореф. дисс. - канд. мед. наук. Москва. 2006. 24 с.
  22. Abbate M., Cravedi P., Iliev I., Remuzzi G., Ruggenenti P. Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives // Curr. Diabetes Rev. 2011. V. 7. № 3. P. 190-200.
  23. Ahn J.A., Moon H.J. Changes in Aqueous Vascular Endothelial Growth Factor and Pigment Epithelium-derived Factor after Ranibizumab Alone or Combined with Verteporfin for Exudative Age-related Macular Degeneration // Am. J. Ophthalmol. 2009. V. 148. P. 718-724.
  24. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., Nguyen H.V., Aiello L.M., Ferrara N., King G.L. Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders // N. Engl. J. Med. V. 331. № 22. P. 1480-1487.
  25. Aiello L.P., Wong J.S. Role of vascular endothelial growth factor in diabetic vascular complications // Kidney Int. 2000. Sep. № 77 (Suppl). P. 113-119.
  26. Aiello L.P. Diabetic Retinopathy - Over Third of Diabetic Patients Don-t Follow Vision Care Guidelines, Health & Medicine Week // Diabetes Care. 1998. V. 21. № 1. P. 143-156.
  27. Antcliff R.J., Marshall J. The pathogenesis of edema in diabetic maculopathy // Semin. Ophthalmol. 1999. V. 14. P. 223-232.
  28. Antonetti D.A., Barber A.J., Khin S., Lieth E., Tarbell J.M., Gardner T.W. and the Penn State Retina Research Group Vascular Permeability in Experimental Diabetes Is Associated With Reduced Endothelial Occludin Content. Vascular Endothelial Growth Factor Decreases Occludin in Retinal Endothelial Cells // Diabetes. 1998. V. 47. P. 1953-1959.
  29. Awata T., Kurihara S., Takata N., Neda T., Iizuka H., Ohkubo T., Osaki M., Watanabe M., Nakashima Y., Inukai K., Inoue I., Kawasaki I., Mori K., Yoneya S., Katayama S. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes // Biochem. Biophys. Res. Commun. 2005. Aug. 5. V. 333(3). P. 679-685.
  30. Boer W.I., Alagappan V.K., Sharma H.S. Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy // Cell. Biochem. Biophys. 2007. V. 47. № 1. P. 131-148.
  31. Campochiaro P.A., Choy D.F.,  Do D.V., Hafiz G., Shah S.M., Nguyen Q.D., Rubio R., Arron J.R. Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples // Ophthalmology. 2009. V. 116. P. 2158-2164.
  32. Chou E., Suzuma I., Way K.J. et al. Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic states: a possible explanation for impaired collateral formation in cardiac tissue // Circulation. 2002. Jan. 22. № 105(3). P. 373-379.
  33. Early treatment diabetic retinopathy study research group. Report №13. Fluorescein angiographic risk factors for progression of diabetic retinopathy // Ophthalmology. 1991. V. 98. № 5. P. 834 - 840.
  34. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis // Am. J. Physiol. Cell. Physiol. 2001. V. 280. № 6. P. 1358 - 1366.
  35. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress // Endocr Rev. 2004. V. 25. № 4.  P. 581 - 611.
  36. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease // Nat. Med. 1995. V. 1. P. 27-31.
  37. Fong G.H., Rossant J., Gertsenstein M., Breitman M.L. Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium // Nature. 1995. V. 376. P. 66-70.
  38. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi E., Hori S. Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor Are related to Diabetic Macular Edema // Ophthalmology. 2003. V. 110. P. 1690-1696.
  39. Funatsu H., Yamashita H., Noma H. et. al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetic macular edema. // Am. J. Ophthalmol. 2002. V. 133. P.70-77.
  40. Funatsu H., Noma H., Mimura T., Eguchi S., Hori S. Association of vitreous inflammatory factors with diabetic macular edema // Ophthalmology. 2009. V. 116. № 1. P. 73-79.
  41. Funatsu H., Yamashita H., Ikeda T., Mimura T., Eguchi S., Hori S. Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor Are Related to Diabetic Macular Edema // Ophthalmology. 2003. V. 110. P. 1690-1696.
  42. Gardlik R., Celec P., Bernadic M. Targeting angiogenesis for cancer (gene) therapy // Bratisl Lek Listy. 2011. V. 112. № 8. P. 428-434.
  43. Gerber H.P., Hillan K.J., Ryan A.M., Kowalski J., Keller G.-A., Rangell L., Wright B.D., Radtke F., Aguet M., Ferrara N. VEGF is required for growth and survival in neonatal mice // Development. 1999. V. 126. P. 1149-1159.
  44. Guo D., Jia Q., Song H.Y., Warren R.S., Donner D.B. Vascular endothelial cell growth factor promotes tyrosine phosphorylation of mediators of signal transduction that contain SH2 domains. Association with endothelial cell proliferation //  J. Biol. Chem. 1995. V. 270. P. 6729 - 6733.
  45. Harhaj N., Felinski E.A., Wolpert E.B., Sundstrom J. M., Gardner T.W., Antonetti D.A. VEGF Activation of Protein Kinase C Stimulates Occludin Phosphorylation and Contributes to Endothelial Permeability // Invest. Ophthalmol. Vis. Sci. 2006. V. 47. P. 5106-5115.
  46. Houck K.A., Ferrara N., Winer J., Cachianes G., Li B., Leung D.W. The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA // Mol. Endocrinol. 1991. V. 5. P. 1806-1814.
  47. Hughes J.M., Brim A., Witmer A.N., Hanraads-de Riemer M., Klaassen I., Schlingemann R.O. Vascular leucocyte adhesion molecules unaltered in human retina in diabetes // Br. J. Ophthalmol. 2004. V. 88. № 4. P. 566 - 572.
  48. Jingjing L., Xue Y., Agarwal N., Roque R.S. Human Muller cells express VEGF183, a novel spliced variant of vascular endothelial growth factor // Invest. Ophthalmol. Vis. Sci. 1999. V. 40. P. 752-759.
  49. Joussen A.M., Kirchhof B., Gottstein C. Molecular mechanisms of vasculogenesis and angiogenesis. What regulates vascular growth - // Ophthalmologe. 2003. V. 100. V. 4. P. 284-291.
  50. Kern T.S. Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy // Exp. Diabetes Res. - Exp. Diabetes Res. 2007. P. 95 103.
  51. Keyt B.A., Berleau L.T., Nguyen H.V., Chen H., Heinsohn H., Vandlen R., Ferrara N. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency // J. Biol. Chem. 1996. V. 271. P. 7788-7795.
  52. Kim K.S., Choi H.M., Lee Y.A., Choi I.A., Lee S.H., Hong S.J., Yang H.I., Yoo M.C. Expression levels and association of gelatinases MMP-2 and MMP-9 and collagenases MMP-1 and MMP-13 with VEGF in synovial fluid of patients with arthritis // Rheumatol Int. 2011. V. 31. № 4. P. 543-547.
  53. Klеin В.Е.К., Кlein К., Моss S.Е. еt аl. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema // Ophthalmology. 1984. V. 91. P. 1464 - 1474.
  54. Kohner E. M. Diabetic retinopathy // Brit. Med. Bull. 1989. V. 5. № 1. P. 148173.
  55. Kubota S., Ozawa Y., Kurihara T., Sasaki M., Yuki K., Miyake S., Noda K., Ishida S., Tsubota K. Roles of AMP-Activated Protein Kinase in Diabetes-Induced RetinalInflammation // Invest. Ophthalmol. Vis. Sci. 2011.
  56. Kuroki M., Kawakami M. Diabetic retinopathy - the mechanisms of the ocular neovascularization and the development of the antiangiogenic drugs // Nipon Rinsho. 1999. V. 57. № 3. P. 584-589.
  57. Lantry L. E. Ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications // Curr. Opin. Mol. Ther. 2007.V. 9. № 6. P. 592-602.
  58. Liu C., Liang B., Wang Q., Wu J., Zou M.H. Activation of AMP-activated protein kinase alpha1 alleviates endothelial cell apoptosis by increasing the expression of anti-apoptotic proteins Bcl-2 and survivin // J. Biol. Chem. V. 2010. V. 285. № 20. P. 15346-15355.
  59. Ma Y.,Zhang Y., Zhao T., Jiang Y.R. Vascular Endothelial Growth Factor in Plasma and Vitreous Fluid of Patients with Proliferative Diabetic Retinopathy. Patients after Intravitreal Injection of Bevacizumab // Am. J. Ophthalmol. 2011. P. 3439.
  60. Migdal M., Huppertz B., Tessler S., Comforti A., Shibuya M., Reich R., Baumann H., Neufeld G. Neuropilin-1 is a placenta growth factor-2 receptor // J. Biol. Chem. 1998. V. 273. P. 2227222278.
  61. Mishra A., Bhattacharya P., Paul S., Paul R., Swarnakar S. An alternative therapy for idiopathic pulmonary fibrosis by doxycycline through matrix metalloproteinase inhibition // Lung. India. 2011. V. 28. P. 3. P. 174-179.
  62. Mitchell P. A systematic review of the efficacy and safety outcomes of anti-VEGF agents used for treating neovascular age-related macular degeneration: comparison of ranibizumab and bevacizumab // Curr. Med. Res. Opin. 2011. V. 27. № 7. Р. 1465-1475.
  63. Moses M. A. The regulation of neovascularisation by matrix metalloproteinases and their inhibitors // Stem Cells. 1997. № 15. P. 180-189.
  64. Murakami T.,  Felinski E.A., Antonetti D.A. Occludin Phosphorylation and Ubiquitination Regulate Tight Junction Trafficking and Vascular Endothelial Growth Factor-induced Permeability // J. Biol. Chem. 2009. V. 284. № 31. P. 21036-21046.
  65. Nayak R.C., Agardh C.D., Kwok M.G., Stjernquist H., Farthing-Nayak P.J., Agardh E. Circulating anti-pericyte autoantibodies are present in type 2 diabetic patients and are associated with non-proliferative retinopathy // Diabetologia. 2003. V. 46. № 4. P. 511 - 513.
  66. Noda K., Ishida S., Inoue M., Obata K., Oguchi Y., Okada Y., Ikeda E. Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy // Investigative Ophthalmology and Visual Science. 2003. Т. 44. № 5. P. 2163-2170.
  67. Ortega N., Hutchings H., Plouet J. Signal relays in the VEGF system // Front. Biosci. 1999. V. 4. Р. 141-152.
  68. Ortega N., Jonca F., Vincent S., Favard C., Ruchoux M.M., Plouet. J. Systemic activation of the vascular endothelial growth factor receptor KDR/flk-1 selectively triggers endothelial cells with an angiogenic phenotype // Am. J. Pathol. 1997. V. 151. Р. 1215-1224.
  69. Rao A. Anti-VEGF and intraocular pressure // Br. J. Ophthalmol. 2011. V. 95. № 11. P. 16 - 18.
  70. Robich M.P., Osipov R.M., Chu L.M., Feng J., Burgess T.A., Oyamada S., Clements R.T., Laham R.J., Sellke F.W. Temporal and spatial changes in collateral formation and function during chronic myocardial ischemia // J. Am. Coll. Surg. 2010. V. 211. № 4. P. 470-80.
  71. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness // World J. Diabetes. 2011. 15. V. 2(6). Р. 98-104.
  72. Selim K.M., Sahan D., Muhittin T., Osman C., Mustafa O. Increased levels of vascular endothelial growth factor in the aqueous humor of patients with diabetic retinopathy // Indian. J. Ophthalmol. 2010. V. 58. № 5. P. 375-379.
  73. Shen C., Li Q., Zhang Y.C., Ma G., Feng Y., Zhu Q., Dai Q., Chen Z., Yao Y., Chen L., Jiang Y., Liu N. Advanced glycation endproducts increase EPC apoptosis and decrease nitric oxide release via MAPK pathways // Biomed Pharmacother. 2010. V. 64. № 1. P. 35-43.
  74. Szaflik J.P., Wysocki T., Kowalski M., Majsterek I., Borucka A.I., Blasiak J., Szaflik J. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy // Graefes. Arch. Clin. Exp. Ophthalmol. 2008. V. 246. V. 1. P. 39-43.
  75. Takahashi T., Ueno H., Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells // Oncogene. 1999. V. 18. P. 2221-2230.
  76. Takahashi T., Yamaguchi S., Chida K., Shibuya M. A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-γ and DNA synthesis in vascular endothelial cells // EMBO J. 2001. V. 20.  P. 2768-2778.
  77. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J.C., Abraham J.A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing // J. Biol. Chem. 1991. V. 266. P. 11947-11954.
  78. Tugues S., Koch S., Gualandi L., Li X., Claesson-Welsh L. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer // Mol. Aspects. Med. 2011. V. 32. № 2. P. 88-111.
  79. Vincenti V., Cassano C., Rocchi M., Persico G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. // Circulation. 1996. V. 93. P. 1493 - 149.
  80. Walters E.H., Reid D., Soltani A., Ward C. Angiogenesis: a potentially critical part of remodelling in chronic airway diseases // Pharmacol. Ther. 2008. V. 118. № 1. P. 128 - 137.
  81. Watson P.M., Anderson J.M., Van Itallie C.M., Doctrow S.R. The tight- junction - specific protein ZO-1 is a component of the human and rat blood-brain barriers // Neurosci. Lett. 1999. V. 129. P. 6-10.